<SEC-DOCUMENT>0001213900-24-065405.txt : 20240806
<SEC-HEADER>0001213900-24-065405.hdr.sgml : 20240806
<ACCEPTANCE-DATETIME>20240806092739
ACCESSION NUMBER:		0001213900-24-065405
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240806
FILED AS OF DATE:		20240806
DATE AS OF CHANGE:		20240806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SciSparc Ltd.
		CENTRAL INDEX KEY:			0001611746
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38041
		FILM NUMBER:		241177571

	BUSINESS ADDRESS:	
		STREET 1:		20 RAUL WALLENBERG STREET, TOWER A
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916
		BUSINESS PHONE:		972-3-6103100

	MAIL ADDRESS:	
		STREET 1:		20 RAUL WALLENBERG STREET, TOWER A
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SciSparc Ltd./ADR
		DATE OF NAME CHANGE:	20210129

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Therapix Biosciences Ltd.
		DATE OF NAME CHANGE:	20140624
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea021070102-6k_scisparc.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Report of Foreign Private Issuer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of August 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission file number: 001-38041</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SCISPARC LTD.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>20 Raul Wallenberg Street, Tower A,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Tel Aviv 6971916 Israel</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F &#9746; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 6, 2024, SciSparc
Ltd. (the &ldquo;Company&rdquo;) issued a press release titled &ldquo;SciSparc&rsquo;s Collaboration with Clearmind Medicine Continues
to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug.&rdquo; A copy of this press release is furnished
herewith as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K and is incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Report of Foreign Private Issuer on Form 6-K is incorporated
by reference into the Company&rsquo;s registration statements on Form F-3 (File Nos. <A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390023083494/ea187529-f3_scisparc.htm">333-275305</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390023012516/ea172999-f3_scisparc.htm">333-269839</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390022037966/ea162219-f3_scisparcltd.htm">333-266047</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390019016523/ff32019_therapixbio.htm">333-233417</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390022022376/ea158932-posam_scisparcltd.htm">333-248670</A>
and <A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390023018886/ea174796-posam_scisparc.htm">333-255408</A>) and on Form S-8 (File Nos. <A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390024028880/ea0203015-s8_scisparc.htm">333-278437</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390018008005/fs82018_therapixbiosciences.htm">333-225773</A>) filed with the Securities and Exchange Commission to be a part thereof
from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%; border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 90%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea021070102ex99-1_scisparc.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release issued by SciSparc Ltd., titled &ldquo;SciSparc&rsquo;s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug.&rdquo;</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SciSparc Ltd.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: August 6, 2024</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 35%; border-bottom: black 1.5pt solid">/s/ Oz Adler</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp; </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oz Adler</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">3</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea021070102ex99-1_scisparc.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY SCISPARC LTD., TITLED "SCISPARC'S COLLABORATION WITH CLEARMIND MEDICINE CONTINUES TO BEAR FRUIT WITH NEW SCIENTIFIC ARTICLE SHOWING MEAI POTENTIAL AS A NOVEL WEIGHT LOSS DRUG."
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 18pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex99-1_001.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>SciSparc&rsquo;s
Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss
Drug</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>SciSparc has been collaborating with Clearmind
Medicine to create effective treatments for obesity and metabolic syndrome by combining SciSparc&rsquo;s Palmitoylethanolamide (PEA) with
Clearmind&rsquo;s MEAI</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">TEL AVIV, Israel, August 6, 2024 (GLOBE
NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the &ldquo;Company&rdquo; or &ldquo;SciSparc&rdquo;), a specialty clinical-stage pharmaceutical
company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, today announced that
a new article published by Baraghithy et al. on the promising results from a recent study on 5-methoxy-2-aminoindane (&ldquo;MEAI&rdquo;),
Clearmind Medicine Inc&rsquo;s (Nasdaq: CMND) (&ldquo;Clearmind&rdquo; or &ldquo;Clearmind Medicine&rdquo;) <FONT STYLE="background-color: white">innovative
psychoactive molecule,</FONT> for combating obesity. The study was meticulously conducted by a team of experts led by Prof. Joseph Tam,
head of the </FONT>Obesity and Metabolism Laboratory at the School of Pharmacy at the Hebrew University of Jerusalem<FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This comprehensive study was published in ACS Pharmacology and Translational
Science,&nbsp;https://pubs.acs.org/doi/epdf/10.1021/acsptsci.4c00353<U STYLE="text-decoration: none">.</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SciSparc and Clearmind have been collaborating since 2022 to develop
innovative proprietary combinations for effective and safe treatments for addictions and for obesity and metabolic syndrome. These treatments
are based on various combinations therapies including SciSparc&rsquo;s Palmitoylethanolamide (PEA) and Clearmind&rsquo;s MEAI. Their joint
efforts have led to multiple patent applications aiming to offer safer and more effective therapeutic options. This collaboration leverages
Clearmind&rsquo;s expertise in psychedelic-derived therapeutics and SciSparc&rsquo;s cannabinoid-based pharmaceutical innovations.
SciSparc and Clearmind jointly fund various studies and IP related to their collaboration.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Key findings from the study demonstrated that the treatment significantly
reduced weight loss, in diet-induced obesity in mice, by decreasing fat mass while preserving lean mass. There was a significant improvement
in glucose metabolism, increased energy expenditure and fat utilization, while maintaining a similar food consumption and increased activity-specific
energy expenditure (without overstimulation), providing support for its potential to impact energy balance. Furthermore, there was a decrease
in fatty liver, as evidenced by lower liver triglyceride and cholesterol levels, mainly through inhibiting new lipid synthesis and reducing
fat accumulation.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These results further show that a combination treatment was well tolerated
and led to increased oxygen consumption and carbon dioxide emission, coupled with elevated energy expenditure and fat oxidation which
in turn indicates increases in the metabolic process and fat burn.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About SciSparc Ltd. (Nasdaq: SPRC):</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SciSparc Ltd. is a specialty clinical-stage pharmaceutical company
led by an experienced team of senior executives and scientists. SciSparc&rsquo;s focus is on creating and enhancing a portfolio of technologies
and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs
based on THC and/or non-psychoactive cannabidiol: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer&rsquo;s disease
and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism and status epilepticus. The Company also owns
a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds&rsquo; oil-based products on the&nbsp;Amazon.com&nbsp;Marketplace.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Clearmind Medicine Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Clearmind is a clinical-stage psychedelic pharmaceutical biotech company
focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems,
including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize
them as regulated medicines, foods or supplements. The Company&rsquo;s intellectual portfolio currently consists of nineteen patent families
including 28 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic
regarding the acquisition of additional intellectual property to build its portfolio. Shares of Clearmind are listed for trading on Nasdaq
under the symbol &ldquo;CMND&rdquo; and the Frankfurt Stock Exchange under the symbol &ldquo;CWY0.&rdquo;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements:</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release contains forward-looking statements within the meaning
of the &ldquo;safe harbor&rdquo; provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For
example, SciSparc is using forward-looking statements when it discusses potential to create effective treatments for obesity and metabolic
syndrome by combining SciSparc&rsquo;s Palmitoylethanolamide with Clearmind&rsquo;s MEAI. The Company may not enter into or complete a
definitive agreement for the proposed transaction with the biotechnology company or, even if it does, it may not create shareholder value.
Since such statements deal with future events and are based on SciSparc&rsquo;s current expectations, they are subject to various risks
and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied
by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other
risks and uncertainties, including those discussed under the heading &ldquo;Risk Factors&rdquo; in SciSparc&rsquo;s Annual Report on Form 20-F
filed with the SEC on&nbsp;April 1, 2024, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise
required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as
of the date they were made, whether as a result of new information, future events or circumstances or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investor Contact:<BR>
IR@scisparc.com<BR>
Tel: +972-3-6167055</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "6 )8# 2(  A$! Q$!_\0
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M, =6( ))]:KQ?\))>:1XM\ RZB]SJMK:A["_<[7G@D!PKGLW!4GWJM;S^(_
M'B2/PGID=A<Z-?EY=(>_D=!&Q.6@WJ#G&20".1WKM?"GAF\TR]U'6-:NHKO6
M]2*^>\*E8HHU&%C0'G R>3UH YB!M7U[PI#X1L_"-WHEO) +:]N+I42*&/&'
M\H DR,><' ZY-=+9>";=-!T#3]2NYKN?0Y5EMKE?W;$KD*#UR-I ([XKK:*
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M[@8_.@#IJ*** "BBB@ HHHH **** "N7^(JL_P .?$*JI9C82@ #)/RUU%%
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MQ6\6UW-$CNP4$XSD @'IWJWIFA:5HT/EZ7IMI9H1@B"%4S]<#FBB@#2HHHH
..**** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
